Conclusions: Changes from baseline in u5-HIAA, BMs and flushing suggest a trend towards meaningful efficacy of TE þ LAN in CSD, in a population with moderately elevated baseline BM frequency. The combination TE þ LAN was generally well tolerated. No power calculation was performed for this exploratory post hoc analysis; imbalanced groups and low patient numbers preclude any formal comparison with PBO. Evaluation of this TE þ LAN regimen as first-line therapy in patients with CSD may be warranted. Clinical trial identification: TELESTAR: NCT01677910 TELECAST: NCT02063659. Background: Treatment with somatostatin analogs (SSA) in monotherapy is the most attractive first-line option for most patients with well-differentiated stage IV unresectable gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The objective is to develop and internally validate tool for predicting progression-free survival (PFS) during treatment with SSA. Methods: The GETNE-TRASGU study is a subanalysis of the Spanish Group of NETs registry (R-GETNE). The cohort contains 309 patients treated between 2000-2017 with SSA in the first-line of advanced disease. PFS data were evaluated using Cox proportional risk regression and graphically represented as a nomogram. Missing data were controlled by multiple imputation. Bootstrap Harrell's c-index with 150 replications was used to assess discrimination. Results: The median PFS was 25.5 months (95% CI, 20.8-30.8). The nomogram contains 5 covariates significantly associated with PFS: Ki67% index, neutrophil-lymphocyte ratio (NLR), extrahepatic metastases, liver tumor burden and primary tumor location. The median PFS was 3.7 (95% CI, 2. Conclusions: The GETNE-TRASGU nomogram allows stratification of patients with advanced and well-differentiated GEP-NETs into four prognostic groups, with potential implications for treatment selection. Legal entity responsible for the study: Grupo Español de Tumores Endocrinos y Neuroendocrinos (GETNE).
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Background: Treatment with somatostatin analogs (SSA) in monotherapy is the most attractive first-line option for most patients with well-differentiated stage IV unresectable gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The objective is to develop and internally validate tool for predicting progression-free survival (PFS) during treatment with SSA. Methods: The GETNE-TRASGU study is a subanalysis of the Spanish Group of NETs registry (R-GETNE). The cohort contains 309 patients treated between 2000-2017 with SSA in the first-line of advanced disease. PFS data were evaluated using Cox proportional risk regression and graphically represented as a nomogram. Missing data were controlled by multiple imputation. Bootstrap Harrell's c-index with 150 replications was used to assess discrimination. Results: The median PFS was 25.5 months (95% CI, ). The nomogram contains 5 covariates significantly associated with PFS: Ki67% index, neutrophil-lymphocyte ratio (NLR), extrahepatic metastases, liver tumor burden and primary tumor location. The median PFS was 3.7 (95% CI, 2.5-not computable) in poor prognosis group, 8.3 (95% CI, 18.4 (95% CI, Lu-DOTATATE (Lu)(n ¼ 117) or high-dose octreotide (Oct) (n ¼ 114). The liver tumor burden (LTB) was defined as tumor volume/total liver volume by CT, and categorized as low (<25%), moderate (25-50%), and high (>50%). PFS, QoL and hepatotoxicity were assessed based on baseline LTB. QoL was analysed using EQRTC QLQC 30 and G.I. NET 21 questionnaires completed at baseline and every 12 weeks thereafter for low and moderate/high LTB subgroups. Deterioriation was defined if the score decreased by 10 points at any time point after baseline. Time to deterioration (TTD) was defined as the time from randomization to the first QoL deterioration. In Lu arm, Grade 3/4 (CTCAE v 4.03) AST and ALT toxicities occurred in the low LTB in 2 and 3 patients, and in the high LTB group in 3 and 1 patients, respectively. Grade 3/4 hyperbilirubinemia occurred in one patient from the low LTB and one from the moderate LTB group. All liver function tests abnormalities were resolved without sequela. There were no high grade ALT, AST and Biliriubin toxicities in Oct arm.
Conclusions:
177 Lu-DOTATATE treatment demonstrated significant PFS improvement regardless of the extent of baseline liver tumor burden in patients with well-differentiated, metastatic midgut NET. Clinically significant liver function test abnormalities were rare, were not associated with high liver tumor burden, and resolved without sequela. The analysis shows that 
1317P Treatment outcomes for well differentiated grade 3 neuroendocrine tumors (NET G3)
Retrospective data suggest that commonly applied first-line chemotherapy protocols with cisplatin or carboplatin in combination with etoposide (PE) are less effective in NET G3 than NEC G3. Therefore current treatment guidelines suggest alternative firstline treatment with protocols like temozolomide-based (TEM) which have only been evaluated in second-line so far. Methods: Records of pts diagnosed with advanced EP-PD-NEC and treated with CB/ oral-ET and CB/IV-ET were reviewed retrospectively (09/96-02/17). First-line survival/ activity/toxicity data are reported. Results: One-hundred-thirteen pts were identified: median (med) follow-up was 11.5 months (m); med age was 65.8 years (range 24-88); male¼64%; ECOG performance status 0-1¼81%; no/mild comorbidities¼81%; gastro-entero-pancreatic origin¼54%; stage IV ¼ 90% (53% liver metastases). Median Ki-67¼70% (95%CI 60-80%), Ki-67>55%¼59%. A total of 123 courses of CB-ET were administered: 106 (86%) 1L, 16 (13%) 2 nd -line (2L) and 1 (1%) 3 rd -line; med cycles/line¼4; oral-ET 45%, IV-ET 55%. Median CB-ET dose-intensity (available for 82 courses): 96% (1L), 90% (2L). Median 1L-progression free survival (PFS) was 5.9m (95%CI 5.0-7.1): oral-ET 5.6m, IV-ET 6.2m, hazard ratio (HR)¼0.76 (95%CI 0.51-1.14). Median 1L-overall survival (OS) was 11.5m (95%CI 8.9-13.6): oral-ET 8.9m, IV-ET 12.1m, HR ¼ 0.68 (95%CI 0.45-1.03), p ¼ 0.07. Radiological response (assessed for 95 pts), 1L-disease control rate was 75.8% (95%CI 67.1-84.6): oral-ET 69.8% (95%CI 55.5-84.1), IV-ET 80.8% . Liver metastases were the only independent factor related to worse 1L-PFS on multivariable analysis, HR ¼ 1.71 (95%CI 1.11-2.63). Commonest 1L-grade 3-4 adverse event (AE) was myelosuppression (47.2%); no significant differences between oral-ET and IV-ET AEs, except for venous thromboembolism; oral-ET 12.5%, IV-ET 1.7% (p ¼ 0.04). Conclusions: This is one of the largest series of pts with advanced EP-PD-NEC treated with CB-ET in the current literature. Oral-ET and IV-ET schedules are associated with comparable 1L-PFS/activity/toxicity data. There is a trend towards better 1L-OS for IV-ET schedules; this, however, may be driven by differences in patient selection between the two subgroups. Legal entity responsible for the study: The Christie NHS Foundation Trust. Funding: Has not received any funding. Disclosure: All authors have declared no conflicts of interest.
